^
Association details:
Biomarker:No biomarker
Cancer:Waldenstrom Macroglobulinemia
Regimen:BDR (bortezomib + dexamethasone injection + Rituxan (rituximab))
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: PRIMARY THERAPY FOR WM/LPL...Preferred Regimens...Bortezomib/dexamethasone/rituximab